Skip to main content

Advertisement

Advertisement

Advertisement

Advertisement

ADVERTISEMENT

Conference Coverage

Should Docetaxel Plus Ramucirumab Be the Standard Second-Line Option for Patients With Non-Small Cell Lung Cancer?

Edward Garon, MD


At the Great Debates and Updates in Lung Cancer Meeting in New York, New York, Edward Garon, MD, UCLA Jonsson Comprehensive Cancer Center, Santa Monica, California, argued that docetaxel plus ramucirumab should be the standard second-line option for patients with NSCLC. 


Source: 

Garon E. Debate: Is Docetaxel + ramucirumab the standard second-line? Presented at Great Debates & Updates in Lung Cancer; April 27-28, 2024; New York, NY.

© 2024 HMP Global. All Rights Reserved.
Any views and opinions expressed are those of the author(s) and/or participants and do not necessarily reflect the views, policy, or position of Oncology Learning Network or HMP Global, their employees, and affiliates. 

Advertisement

Advertisement

Advertisement

Advertisement